Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug Biktarvy in a late-stage study involving previously untreated adult ...

Gilead Sciences (GILD) just got a confidence boost from Wall Street, with Truist initiating coverage at Buy and Mizuho ...

Gilead Sciences, Inc. (NASDAQ:GILD) ranks among the best slow growth stocks to invest in. On November 21, Mizuho increased ...

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read more on GILD stock here.

Gilead Sciences has received permission from the Food and Drug Administration for an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy (bictegravir 50 ...

While Gilead saw high demand for several of its top products in the first quarter, a $2.7 billion write-down on its cancer efforts put a big dent in earnings. Gilead's HIV combo med Biktarvy and COVID ...

(RTTNews) - Gilead Sciences Inc.'s (GILD) Biktarvy demonstrated high efficacy for a broad range of people initiating treatment for HIV, including those with hepatitis B or HBV coinfection, as per ...

Gilead Sciences' triple-threat Biktarvy is already a standout in the HIV treatment space—and it’s the company's top seller, to boot. Now, Gilead is trumpeting data that could pave the way to millions ...

The Food and Drug Administration has given Gilead the green light for a new low-dose tablet dosage form of Biktarvy (bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg tablets) for ...

– Phase 3 Data from the BRAAVE 2020 Study in Black or African American Virologically Suppressed Adults Presented, Including Patients with a History of Treatment Failure or Pre-Existing Resistance – – ...

Please provide your email address to receive an email when new articles are posted on . Gilead Sciences said the FDA has approved a new low-dose tablet form of its HIV drug Biktarvy for pediatric ...

DUBLIN--(BUSINESS WIRE)--The "Biktarvy - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering. Biktarvy - Drug Insight, 2019 report provides comprehensive information of the ...